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Take-home message: Haloperidol is, independently of delirium subtype, still the first choice for 
pharmacological management of delirium, followed by benzodiazepines and dexmedetomidine. Circulatory 
support is an additional risk factor for receiving haloperidol.  
Tweet: Haloperidol is, independently of delirium subtype, still the first choice of intervention for ICU delirium.  
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Abstract 
Purpose: We assessed the prevalence and variables associated with haloperidol use for delirium in ICU patients 
and explored any associations of haloperidol use with 90-day mortality. 
Methods: All acutely admitted, adult ICU patients were screened during a 2-week inception period. We 
followed the patient throughout their ICU stay and assessed 90-day mortality. We assessed patients and their 
variables in the first 24 and 72 hours in ICU and studied their association together with that of ICU 
characteristics with haloperidol use. 
Results: We included 1260 patients from 99 ICUs in 13 countries. Delirium occurred in 314/1260 patients (25% 
(95% confidence interval 23-27)) of whom 145 received haloperidol (46% (41-52)). Other interventions for 
delirium were benzodiazepines in 36% (31-42), dexmedetomidine in 21% (17-26), quetiapine in 19% (14-23) 
and olanzapine in 9% (6-12) of the patients with delirium. In the first 24-hours in ICU, all subtypes of delirium 
(hyperactive, adjusted Odds Ratio (aOR) 29.7 (12.9-74.5); mixed 10.0 (5.0-20.2); hypoactive 3.0 (1.2-6.7)) and 
circulatory support 2.7 (1.7-4.3) were associated with haloperidol use. At 72-hours after ICU admission, 
circulatory support remained associated with subsequent use of haloperidol, aOR 2.6 (1.1-6.9). Haloperidol use 
within 0-24 hours and within 0-72 hours of ICU admission was not associated with 90-day mortality (aOR 1.2 
(0.5-2.5); p=0.66) and (aOR 1.9 (1.0-3.9); p=0.07), respectively. 
Conclusions: In our study, haloperidol was the main pharmacological agent used for delirium in adult patients 
regardless of delirium subtype. Benzodiazepines, other anti-psychotics and dexmedetomidine were other 
frequently used agents. Haloperidol use was not statistically significantly associated with increased 90-day 
mortality. 
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Background 
Delirium in critically ill patients is a syndrome with a constellation of symptoms and neurological signs 
explained by pre-existing, established or evolving neurocognitive disorders. Delirium is characterised by a 
reduced ability to direct, focus, sustain and shift attention, reduced orientation to the environment, and 
disturbance in cognition, which develops over a short period of time, and tends to fluctuate in severity during 
the course of a day[1]. The pathophysiology of delirium remains poorly understood[2,3]. 
The observed prevalence of delirium in adult ICU patients ranges from 26% to 80%[4,5]; mixed and hypoactive 
subtypes of delirium are more common than the hyperactive subtype[6]. The most valid and recommended 
monitoring tools for routine assessment of delirium in ICU are the Confusion Assessment Method (CAM-ICU) 
and Intensive Care Delirium Screening Checklist (ICDSC)[7]. 
Delirium has been associated with worse outcomes in mechanically ventilated patients[7–10] and more 
complications including Acute Respiratory Distress Syndrome, nosocomial pneumonia and arrhythmia[12]. 
Delirium in mechanically ventilated patients has been associated with up to 30% higher ICU, hospital costs and 
long-term cognitive impairment[13,14]. 
The 2002 iteration of the clinical practice guidelines for the management of pain, agitation and delirium of 
adult patients in the ICU recommended haloperidol as the pharmacological agent for delirium[15]. However, in 
the 2013 update of the guideline, this recommendation was changed; haloperidol was no longer recommended 
for delirium in adult ICU patients due to the lack of evidence of effect[16]. The same guideline suggested that 
atypical antipsychotics and continuous intravenous (IV) infusion of dexmedetomidine rather than 
benzodiazepines may reduce the duration of delirium in ICU patients, even though these interventions also 
have a low level of evidence[16]. Currently, there are no pharmacological agents with solid evidence of effect 
on delirium, therefore, ICU clinicians have to rely on their own judgement whether or not to use haloperidol or 
other pharmacological agents. We hypothesised that many ICU patients receive haloperidol even though 
clinical guidelines advice otherwise. 
Our aim was to describe, in a multinational cohort of adult ICU patients, the proportion of patients intervened 
with haloperidol for delirium and variables associated with the use of haloperidol including delirium subtypes. 
We also aimed to describe the use of other pharmacological agents for delirium management in the ICU and to 
explore the association of haloperidol with 90-day mortality. 
Methods 
We performed a multinational, prospective 2-week inception cohort study including 99 ICUs from Belgium, 
Brazil, Canada, Denmark, Finland, France, Germany, Italy, the Netherlands, Norway, Spain, Sweden and 
Switzerland. The study protocol was published before study conduct (http://www.cric.nu/aid-icu-national-
principal-investigators/). We use the STROBE (Strengthening the reporting of observational studies in 
epidemiology) statement when reporting this manuscript[17]. 
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Each country coordinator recruited ICUs to participate within their country. Participation was voluntary and no 
reimbursement was given. Each participating ICU selected a 2-week period between March 7th and June 30th 
2016 for patient enrolment. 
Study population 
All patients admitted to the participating ICUs within the 2-week inception period were screened and those 
admitted acutely who were aged 18 years or older were included. Exclusion criteria were: diagnosis of mental 
illness including schizophrenia, psychosis or major depression; neuro-degenerative disorders such as dementia 
or Parkinson’s disease; institutionalisation for mental illness or cognitive mental retardation; previous 
congenital or acquired brain damage; stroke within the last 2 weeks; ongoing seizures; suspected anoxic brain 
injury or acute traumatic brain injury; hospitalisation within the last 6 months for hepatic coma, drug overdose 
or suicide attempt; and severe vision or hearing impairment.  
Definitions of delirium and coma 
Several delirium screening tools were approved for the study. The patient was diagnosed as having delirium if 
CAM-ICU was positive[18], ICDSC was 4 or above[19], Delirium Observation Screening (DOS) was above 3[20], 
or Nursing Delirium Screening Scale (Nu-DESC) was 2 or above[21] at least once a day during the ICU admission. 
We subtyped delirium during ICU stay as hypoactive only (lying still with open eyes and no clear contact (even 
with a Glasgow Coma Scale (GCS) score ≥ 8 or Reaction Level Scale (RLS) < 4) [22], hyperactive delirium only 
(agitated and non-cooperative, pulling tubes and catheters) or mixed (if both hypo- and hyperactive delirium 
were present during ICU stay)[6]. We defined coma as Richmond Agitation Sedation Scale (RASS) between -3 to 
-5[23], Ramsay sedation score was between 4 to 6[24], Riker Sedation-Agitation Scale (SAS) 1 and 2[25], Motor 
Activity Assessment Scale (MASS) 1 to 0[26], GCS score below 8 without sedation or RLS above 3 without 
sedation. 
Outcomes 
The primary outcome was the number of patients with delirium intervened with haloperidol. Secondary 
outcomes were the number of patients with delirium intervened with antipsychotics other than haloperidol, 
days alive out of ICU without coma or delirium, days alive without mechanical ventilation, and days alive out of 
hospital within the 90-days follow-up period. Finally, we investigated the relation between haloperidol use in 
the ICU and 90-day mortality.   
Data collection 
On ICU admission, we recorded ICU admission diagnosis, presence of known risk factors for delirium prior to 
hospital and ICU admission (smoking, substance, alcohol- and benzodiazepine abuse, vision and hearing 
impairment), and a modified Simplified Acute Physiology Score (SAPS) II [27], excluding PaO2/FiO2 ratio, urinary 
output and s-bilirubin level due to the expectation of many missing values for these variables[28]. We assessed 
for the presence of delirium, delirium subtype and coma, and pharmacological interventions for delirium daily. 
Interventions recorded included haloperidol, olanzapine, and quetiapine as mg/day, administrated as fixed or 
per needed dosage and if it was given as prophylaxis or treatment against delirium. Furthermore, we recorded 
if the antipsychotics were prescribed as prophylaxis or treatment. We recorded the use of dexmedetomidine at 
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night when administrated for more than 4 continuous hours between 10 pm-6 am, the use of physical 
restraint, sedatives (including dexmedetomidine as continuous infusion for more than 12 hours), opioid 
infusions and sleeping medication (benzodiazepines, hypnotics and melatonin). We recorded the use of 
vasopressors, inotropes, mechanical ventilation and renal replacement therapy daily as binary variables. If 
patients were discharged to another ICU participating in the AID-ICU study, data collection was continued. If 
patients were readmitted to a participating ICU, data collection resumed for a maximum of 90 days. At 90 days, 
we obtained vital status, ICU and index hospital length of stay and additional hospital admissions during the 
follow-up period. Registered data were stored in a secure web-based case report form build in OpenClinica 
(www.openclinica.com). 
Ethics 
The study protocol was approved by the Danish Data Protection Agency (No. RH-2016-67, 04509) and the 
Danish Health and Medicines Authority (No. H-3-2014-FSP56). Each country coordinator obtained ethical 
approvals for the study according to national requirements.  
Statistical analyses 
We developed and published the statistical analysis plan prior to the closure of the study database 
(http://www.cric.nu/aid-icu-cohorte-study-statistical-analysis-protocol/). 
Sample size 
Based on preliminary data obtained in Copenhagen in May 2014 (the Department of Intensive Care, 
Rigshospitalet), where 13% of all acutely admitted adult ICU patients were intervened with haloperidol, we 
estimated that at least 1000 patients were needed to obtain a 95% Confidence Interval (CI) of 11%-15% around 
the proportion of ICU patients intervened with haloperidol. 
Descriptive statistics 
Categorical data were presented as numbers and percentages (%) and medians with interquartile ranges (IQR). 
Chi-squared and Wilcoxon rank-sum tests were used to assess differences between patients intervened with 
haloperidol and those not intervened. 
We conducted complete case analyses as we excluded seven patients who had incomplete data after logical 
imputations (ESM, tables 1 and 2). For the 119 patients (9.4%) with missing 90-day mortality data, we assumed 
they were alive and not on a ventilator, in hospital or in coma after their last registered day alive. In a 
supplementary analysis, we assumed that the 119 patients with missing 90-day mortality data were dead.  
Patients receiving haloperidol (n=8) or other antipsychotics (olanzapine = 3, quetiapine = 9) as prophylaxis who 
never had delirium registered during ICU admission were analysed as not having received haloperidol or other 
antipsychotics for delirium.  
Follow-up measurements and outcome analyses 
We used univariate and multiple logistic regression analysis to assess variables associated with haloperidol 
during ICU stay. Variables were based on information from the first 24 hours of ICU admission and the first 72 
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hours of ICU admission, respectively. Results were presented as odds ratio (ORs) with 95% CIs. In the 72-hour 
analysis, we included patients who were alive and still in ICU 72 hours after ICU admission and who had not 
received haloperidol prior to this assessment. Both the 24-h and 72-h analyses were adjusted for the following 
predefined baseline covariates: age, delirium subtype, and use of sedation, mechanical ventilation, circulatory 
support or renal replacement therapy as these were expected to have low missingness and describe risk factors 
in general (age and use of life support)[29] and factors associated with haloperidol use (delirium subtypes). In 
addition, we adjusted for ICU characteristics (number of hospital beds, existence of ICU guidelines for 
identifying and/or using pharmacological or non-pharmacological interventions for delirium and nurse to 
patient ratio as 1:<1, 1:1, 1:>1). 
Univariate and multiple logistic regression analysis were also used to assess the crude and adjusted OR (95% CI) 
for the association between use of haloperidol in the ICU and 90-day mortality. We adjusted this analysis for 
the following predefined baseline covariates (at 24-h and at 72-h): age, delirium subtype, and use of sedation, 
mechanical ventilation, circulatory support or renal replacement therapy, because of expected low level of 
missingness and associations with mortality[29,30] for the same reasons given above. 
A total of five out of the 1260 patients were excluded from the follow-up analysis due to unreliable and 
inconsistent follow-up information that could not be fixed by logical imputations (ESM figure 2).  
We refrained from doing the planned 1-week baseline analysis due to few patients fulfilling the outcomes 
(n=27; alive in the ICU and not exposed to haloperidol in the first week).  
We performed all analyses using R (version 3.2.3) and SAS (version 9.4), used two-tailed tests and considered p 
< 0.05 to indicate statistical significance. 
Results 
We screened 1922 patients in the 99 ICUs from 13 countries (ESM Figure 1 and ESM table 2) and included 1260 
patients in the analyses (ESM Figure 2). The median length of stay in ICU was 2.9 (IQR 1.1-6.6) days.  
Delirium 
A total of 314 of the 1260 patients (24.9% (95% CI 22.6-27.4)) experienced delirium during the ICU stay; 13.1% 
(165/1260), 6.1% (77/1260) and 5.7% (72/1260) of all patients had mixed, hyperactive and hypoactive delirium, 
respectively. The median length of ICU stay for patients with delirium was 7 (IQR 3.3-14.5) days, the median 
number of days with delirium in the ICU was 2 (1-4) days and the median number of days in the ICU before the 
onset of delirium was 3 (2-6) days.  
Haloperidol 
We found that 145/314 (46.2% (95% CI 40.6-51.9)) patients with delirium were intervened with haloperidol 
(the primary outcome). In total, 166/1260 (13.2% (11.4-15.2)) patients received haloperidol in ICU. The median 
number of days before the first dose of haloperidol, for patients with delirium at some point during the ICU 
stay, was 3 (IQR 2-7) days, and the median number of days with the use of haloperidol was 2 (1-5). The median 
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daily and cumulative doses of haloperidol given in the ICU are presented in Table 1. Baseline patient and ICU 
characteristics associated with the use of haloperidol are presented in Table 2. At 24 hours, all delirium 
subtypes and circulatory support were associated with a higher probability of being intervened with 
haloperidol (Table 3). At 72 hours after ICU admission, only circulatory support was associated with the 
subsequent use of haloperidol (Table 3). 
Other pharmacological interventions for delirium 
The most common other agents used against delirium were benzodiazepines in 36.0% (95% CI 30.7-41.6), 
dexmedetomidine in 21.3% (17.2-26.2), quetiapine in 18.5% (14.3-23.2) and olanzapine in 8.6% (5.7-12.3) of 
the 314 patients with delirium. Among the 145 patients with delirium that received haloperidol, 
benzodiazepines were by far the most commonly used second agent (44.8% (36.6-53.3)) (Figure 1).   
Mortality  
The overall 90-day mortality was 20.8% (95% CI 18.6-23.1). After 90 days, 220 of the 1089 (20.2%, (17.8-22.7)) 
patients not receiving haloperidol at any time in the ICU had died compared to 41 (24.7%, (18.3-32.0)) of the 
166 patients receiving haloperidol in the ICU. Among the 168 patients with delirium not intervened with 
haloperidol, 22.6% (16.5-29.7) had died at 90-day follow up as compared with 22.1% (15.6-29.7) among the 
145 patients with delirium intervened with haloperidol at some point during ICU stay. The crude and adjusted 
associations between use of haloperidol within the first 24-h and 72-h and 90-day mortality are presented in 
Figure 2. 
Other outcomes 
The median number of days alive without mechanical ventilation, days alive without coma or delirium, days 
alive out of ICU, and days out of hospital within 90-days are presented in ESM table 5. A total of 217/1260 
patients (17.2%) were at some point physically restrained during ICU stay. 
Discussion 
In this multinational, 2-week inception cohort study, we observed that 12% of acutely admitted adult ICU 
patients received haloperidol for delirium. Regardless of subtypes (hyperactive, mixed and hypoactive) delirium 
was associated with a markedly increased odds of receiving haloperidol. Also circulatory support was a risk 
factor for the use of haloperidol. The use of haloperidol within the first 24 or 72 hours of ICU admission was not 
associated with 90-day mortality in either the crude or adjusted analyses. Other commonly used agents against 
delirium in the ICU patients were benzodiazepines, other antipsychotics and dexmedetomidine.  
We found that the overall use of haloperidol was 13%. The difference between the overall use of haloperidol  
and patients with delirium received haloperidol, might be due to patients in coma receiving haloperidol for 
delirium or that there may be a difference in how patients were perceived as having delirium by clinicians. A 
similar study also found an association between use of antipsychotics in the ICU and delirium[31]. 
The reported prevalence of delirium in our study was 25%, which may be lower than in previous reports with 
rates of 40% in non-mechanical ventilated patients and 60% of mechanically ventilated patients[32,33]. The 
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higher rate reported in previous studies may be attributed to the fact that they excluded patients not expected 
to be in the ICU more than 24 hours and only included mechanically ventilated patients. Both duration of ICU 
stay and mechanical ventilation are known risk factors for delirium in critically ill patients. Also, we used a more 
conservative definition of coma as RASS -3 to (-5), hence delirium was not registered in these patients. This is 
similar to the findings by Haenggi and colleagues in 2013 where the rate of delirium decreased when excluding 
patients with RASS -2 to -3[34].  
In the present study, the modified SAPS II at admission was higher in patients receiving haloperidol than in 
those who did not. We used modified SAPS II at admission and found a lower score than in other similar cohort 
studies[28]. According to our predefined statistical analysis plan, we did not adjust for the modified SAPS II, but 
chose variables with expected complete data (age, mechanical ventilation, circulatory support and renal 
replacement therapy) due to an expected missingness of more than 20% of especially s-bilirubin and urinary 
output at ICU admission in SAPS II[29]. In addition, age and use of life support are important risk factors for 
poor outcome among ICU patients[29,35]. 
The strengths in this study include the prospective design using a 2-week inception period with the inclusion of 
a large number of patients from multiple ICUs in numerous countries, the pre-specified and published protocol 
and statistical analysis plan, the handling and reporting of missing data, and the adjustments for known 
potential confounders. Consequently, we believe that these results have high internal and external validity. 
The limitations of this study include the observational design, which has the inherent risk of confounding by 
indication and residual confounding. Moreover, 40% of the participating ICUs were Danish or Spanish and the 
results may be influenced by national practice and guidelines in these countries. Participation was voluntary 
and not selected to be representative of all ICUs, consequently, the ICUs might differ from those declining and 
those not invited. For delirium detection, we used a pragmatic approach; there were no requirements for use 
of a specific tool for delirium detection. Tools that are not yet validated in ICU patients may have been used at 
some sites thereby affecting the observed delirium incidence. We did not pilot test the definitions of delirium 
subtypes and some misclassification might have occurred. We did not collect data on the potential harm 
associated with the use of haloperidol, including extrapyramidal symptoms[36], tardive dyskinesia, 
cardiovascular effects[37] and neuroleptic malignant syndrome[38]. Finally, delirium is defined as fluctuating 
and one delirium score per day does not necessarily identify all those patients developing this organ failure. We 
had missing data for mortality for 119 who were discharged alive and assumed that these were alive at 90-
days. In our ‘worst case’ sensitivity analysis assuming that they were all dead at day 90, the use of haloperidol 
was associate with increased 90-day mortality. Therefore, we cannot exclude entirely that there might be an 
association.   
In contrast to previous findings[39], we did not find that haloperidol in the entire cohort was associated with 
improved survival. This might be due to differences between the study cohorts. We believe that the effects of 
haloperidol on mortality and other important outcomes can only be assessed in a randomised clinical trial 
(RCT). Such RCTs are warranted as we found a high frequency of the use of haloperidol in our ICU patients with 
delirium, a finding supported by those of another recent cohort study[40]. Combined with our finding of a 25% 
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prevalence of delirium in ICU patients, there is a pressing need for RCTs assessing the overall benefits and 
harms of the use of haloperidol in these patients.   
Conclusions 
In this multinational, prospective cohort study of acutely admitted adult ICU patients, we observed that 
haloperidol was the most common pharmacological intervention for delirium independent of delirium subtype. 
Benzodiazepine, quetiapine, dexmedetomidine and olanzapine were also used in ICU patients with delirium. At 
the 5% statistical significance level, we did not observe that the use of haloperidol was associated with 
increased 90-day mortality. 
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Table 1. Haloperidol use in mg presented as the cumulative dose received during ICU stay and median 
administrated daily dose 
 % of the 1260 patients 
(95% CI) 
Median cum. dose 
in mg (IQR) 
Median daily dose  
in mg (IQR) 
Haloperidol (n=166)  13.2 (11.4-15.2) 18 (6-55) 10 (5-15) 
- as fixed dose  9.8 (8.2-11.5) 12 (5-46)  5 (3-10) 
- as per needed dose 12.4 (10.6-14.3) 10 (5-30)  5 (3-10) 
  
15 
 
Table 2. Baseline characteristics of all patients and stratified by use of haloperidol or not during ICU stay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Modified Simplified Acute Physiology Score (SAPS) II as oxygenation, s-bilirubin and urinary output was not 
included.  
b Comparisons of the groups no use of haloperidol vs. use of haloperidol in ICU by Chi-squared or Wilcoxon 
rank-sum (age and SAPS II) tests. Patients receiving haloperidol or other antipsychotics as prophylaxis without 
delirium during ICU admission (n=8) were not included in the haloperidol group. 
 
  
 All patients 
(N=1260) 
No haloperidol 
(N=1094) 
Haloperidol 
(N=166) 
p-valueb 
     
Age (years) median (IQR)   67 (55-76)   67 (54-76)   69 (57-79)   0.04 
Male, n (%) 779 (61.8) 661 (60.4) 118 (71.1)   0.01 
Admission diagnosis     
Sepsis, n (%) 379 (30.1) 301 (27.5)   78 (47.0) <0.01 
Trauma, n (%) 106 (8.4)   93 (8.5)   13 (7.8)   0.77 
Surgery, n (%) 443 (35.2) 380 (34.7)   63 (38.0)   0.42 
- Emergency surgery, n (%) 300 (23.8) 258 (23.6)   42 (25.3)   0.63 
- Elective surgery n, (%) 143 (11.4) 122 (11.2)   21 (12.7)   0.57 
 
Severity score 
    
SAPS IIa, median (IQR)   32 (24-42)   32 (23-41) 37 (27-47) < 0.01 
Metastatic cancer, n (%)   84 (6.7)   80 (7.3)   4 (2.4)   0.02 
Haematological cancer, n (%)   66 (5.2)   59 (5.4)   7 (4.2)   0.53 
AIDS, n (%)   14 (1.1)   13 (1.2)   1 (0.1)   0.50 
 
Prior to ICU admission 
    
Haloperidol, n (%)   32 (2.5)   14 (1.3)   18 (10.8) <0.01 
Smoking, n (%) 307 (24.4) 258 (23.6)   49 (29.5)   0.10 
Alcohol abuse, n (%) 153 (12.1) 129 (11.8)   24 (14.5)   0.33 
Substance abuse, n (%)   32 (2.5)   27 (2.5)    5 (3.0)   0.68 
Benzodiazepines, n (%) 134 (10.6) 108 (9.9)   26 (15.7)   0.02 
Vision impaired, n (%) 261 (20.7) 219 (20.0)   42 (25.3)   0.12 
Hearing impaired, n (%)   72 (5.7)   59 (5.4)   13 (7.8)   0.21 
 
First 24-hours in ICU admission 
    
In coma, n (%) 479 (38.0) 390 (35.7)   89 (53.6) <0.01 
Deliriumb, n (%) 125 (9.9)   71 (6.5)   54 (32.5) <0.01 
Mechanical ventilation, n (%) 702 (55.7) 581 (53.1) 121 (72.9) <0.01 
Circulatory support, n (%) 569 (45.2) 453 (41.4) 116 (70.1) <0.01 
Renal replacement therapy, n (%) 105 (8.3)   86 (7.9)   19 (11.5)   0.12 
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Table 3. Association between characteristics within the first 24 hours and the first 72 hours of ICU admission 
and the subsequent use of haloperidol in ICU  
 Characteristics in the first 24 hours of ICU 
admission 
Characteristics in the first 72 hours of ICU 
admission 
 1255a patients 504b patients  
 Crude OR (95% CI) Adjustedc OR (95% CI) Crude OR (95% CI) Adjustedc OR (95% CI) 
Delirium     
No 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
  Hyperactive  15.6 (7.9-31.8) 29.7 (12.9-74.5) 0.9 (0.1-3.3) 1.2 (0.2-5.5) 
  Hypoactive    3.1 (1.4-6.4)   3.0 (1.2-6.7) 0.2 (.01-1.1) 0.2 (.01-1.1) 
  Mixed delirium   6.7 (3.6-12.4) 10.0 (5.0-20.2) 0.8 (0.2-2.2) 1.2 (0.3-4.1) 
     
Coma 2.1 (1.5-2.9) - 4.7 (2.4-10.4) - 
     
Renal Replacement Therapy 1.5 (0.8-2.5) 1.0 (0.5-1.7) 1.5 (0.7-2.8) 1.1 (0.5-2.2) 
     
Circulatory support 3.3 (2.3-4.7) 2.7 (1.7-4.3) 4.8 (2.3-11.7) 2.6 (1.1-6.9) 
     
Mechanical ventilation 2.4 (1.7-3.5) 1.5 (0.9-2.6) 7.5 (2.7-31.2) 3.0 (0.9-14.2) 
     
Sedation 2.6 (1.9-3.6) 1.4 (0.9-2.3) 4.3 (2.2-9.6) 1.9 (0.8-5.0) 
     
Age     
18-49 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
50-59 1.7 (1.0-3.1) 1.4 (0.7-2.6) 1.0 (0.4-2.2) 1.0 (0.4-2.4) 
60-74 1.1 (0.7-2.0) 0.6 (0.4-1.3) 0.5 (0.2-1.0) 0.4 (0.2-0.9) 
75+ 1.8 (1.1-3.0) 1.2 (0.7-2.1) 0.7 (0.3-1.5) 0.6 (0.2-1.3) 
     
Nurse to patient ratiod     
1:>1 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
1:1 1.8 (1.2-2.8) 1.8 (1.1-3.0) 2.0 (1.0-3.9) 1.7 (0.7-3.6) 
1:<1 1.1 (0.5-2.0) 1.4 (0.6-3.0) 1.5 (0.4-2.2) 2.2 (0.9-4.3) 
     
Guideline to identify deliriumd 1.0 (0.6-1.4) 1.3 (0.7-2.3) 1.2 (0.7-2.2) 2.2 (0.9-5.3) 
     
Guideline to treat delirium (pharma) d 0.7 (0.5-1.0) 0.6 (0.3-1.2) 0.9 (0.5-1.5) 0.5 (0.2-1.4) 
     
Guideline to treat delirium (non-pharma) d 1.2 (0.9-1.7) 1.6 (1.0-2.6) 1.4 (0.8-2.5) 1.7 (0.8-3.6) 
     
Number of hospital bedsd     
0-249 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
250-499 2.5 (1.1-6.7) 1.6 (0.6-4.9) 4.4 (0.9-81.1) 3.1 (0.5-60.9) 
500-999 3.5 (1.6-9.3) 1.5 (0.6-4.6) 8.3 (1.7-150.3) 4.0 (0.7-76.9) 
1000+ 2.5 (1.1-6.7) 1.6 (0.6-4.8) 6.0 (1.2-109.6) 3.2 (0.6-60.3) 
 
Univariate and multiple logistic regressions analysis was performed with crude and adjusted odds ratios (ORs) with 95% 
confidence intervals (CIs).  
Patients receiving haloperidol or other antipsychotics as prophylaxis with no delirium during ICU admission were excluded 
from the treatment group.  
aFive patients were excluded due to unreliable and inconsistent follow-up data.  
bIn the 72 hours analysis, we included patients who were alive in the ICU if they had not received haloperidol 
prior to this assessment. 
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cAdjusted for the following pre-defined baseline covariates:  age, delirium subtype, use of dialysis, circulatory 
support, mechanical ventilation or sedation, and ICU characteristics (nurse to patient ratio, guidelines to 
identify delirium, guidelines to treat delirium, guidelines (non-pharma) to treat delirium and number of 
hospitals beds).  
d47 patients did not contribute to the adjusted analysis due to missing values. 
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Figure texts 
 
Figure 1. Patients with delirium intervened with other antipsychotics, benzodiazepines and dexmedetomidine 
either alone or in combination with haloperidol. Other agents include other sedatives. 
 
aDexmedetomidine used for more than 4 consecutive hours between 10 pm and 6 am. 
 
 
Figure 2. Odds ratios (95% CI) for 90-day mortality in patients who received haloperidol vs. those who did not 
(reference); crude ORs and those adjusted for baseline variables at 0-24 hours and 0-72 hours after ICU 
admission. Five patients were excluded from these analyses due to inconsistent follow-up data. 
aAnalysis including all patients (n=1255)  
bMultivariate logistic regression analysis adjusted for the pre-defined covariates: age, delirium subtypes, and 
use of sedation, mechanical ventilation, circulatory support and renal replacement therapy. 
cAnalysis including patients who were still in the ICU at 72 hours  (n=583).  
 
 
 
 
